精选75CNBC 财经（RSS）股市
礼来：下一代减肥药将于 2027 年申请批准
Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of its obesity portfolio.
更进一步：量化金融体系
看懂新闻只是起点——沿量化金融路径，把它变成能交付的工程能力